0HTC Stock Overview
A development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.29 |
| 52 Week High | US$1.31 |
| 52 Week Low | US$0.24 |
| Beta | 0.68 |
| 11 Month Change | 10.62% |
| 3 Month Change | -14.02% |
| 1 Year Change | -69.98% |
| 33 Year Change | -97.79% |
| 5 Year Change | -98.77% |
| Change since IPO | -98.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HTC | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -6.8% | -2.3% | 0.8% |
| 1Y | -70.0% | -2.7% | 6.6% |
Return vs Industry: 0HTC underperformed the UK Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 0HTC underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0HTC volatility | |
|---|---|
| 0HTC Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HTC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HTC's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 55 | Chris Posner | www.caratherapeutics.com |
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
Cara Therapeutics, Inc. Fundamentals Summary
| 0HTC fundamental statistics | |
|---|---|
| Market cap | US$17.01m |
| Earnings (TTM) | -US$95.52m |
| Revenue (TTM) | US$8.69m |
2.0x
P/S Ratio-0.2x
P/E RatioIs 0HTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HTC income statement (TTM) | |
|---|---|
| Revenue | US$8.69m |
| Cost of Revenue | US$111.11m |
| Gross Profit | -US$102.42m |
| Other Expenses | -US$6.90m |
| Earnings | -US$95.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | -1,179.18% |
| Net Profit Margin | -1,099.76% |
| Debt/Equity Ratio | 5,740.2% |
How did 0HTC perform over the long term?
See historical performance and comparison